Real-world NUDT15 genotyping and thiopurine treatment optimization in inflammatory bowel disease: a multicenter study
ConclusionsNUDT15 codon 139 genotyping effectively reduces thiopurine-induced AEs and improves treatment retention rates in IBD patients after genotype-based dose adjustments. This study provides data-driven treatment strategies based on genotype and identifies risk factors for specific AEs, contributing to a refined thiopurine treatment approach. (Source: Journal of Gastroenterology)
Source: Journal of Gastroenterology - April 8, 2024 Category: Gastroenterology Source Type: research
Formulation, Characterization and In Vitro Evaluation of Mesalamine and Bifidobacterium bifidum Loaded Hydrogel Beads in Capsule System for Colon Targeted Delivery
AAPS PharmSciTech. 2024 Mar 14;25(3):61. doi: 10.1208/s12249-024-02764-3.ABSTRACTMesalamine is a first-line drug for the treatment of inflammatory bowel diseases. However, its premature release associated with marketed formulations leads to adverse effects like gastric trouble, vomiting, and diarrhoea. To minimize these side effects, colon-targeted drug delivery is essential. Besides conventional pharmacotherapy, bifidogenic probiotics with anti-inflammatory activity has been reported to elicit a significant impact on the remission of ulcerative colitis. Bifidogenic probiotics being acid-labile necessitate developing a gas...
Source: AAPS PharmSciTech - March 15, 2024 Category: Drugs & Pharmacology Authors: Jagtar Singh Mohit Sharma Harmeet Singh Pinky Arora Puneet Utreja Shubham Kumar Source Type: research
Formulation, Characterization and In Vitro Evaluation of Mesalamine and Bifidobacterium bifidum Loaded Hydrogel Beads in Capsule System for Colon Targeted Delivery
AAPS PharmSciTech. 2024 Mar 14;25(3):61. doi: 10.1208/s12249-024-02764-3.ABSTRACTMesalamine is a first-line drug for the treatment of inflammatory bowel diseases. However, its premature release associated with marketed formulations leads to adverse effects like gastric trouble, vomiting, and diarrhoea. To minimize these side effects, colon-targeted drug delivery is essential. Besides conventional pharmacotherapy, bifidogenic probiotics with anti-inflammatory activity has been reported to elicit a significant impact on the remission of ulcerative colitis. Bifidogenic probiotics being acid-labile necessitate developing a gas...
Source: AAPS PharmSciTech - March 15, 2024 Category: Drugs & Pharmacology Authors: Jagtar Singh Mohit Sharma Harmeet Singh Pinky Arora Puneet Utreja Shubham Kumar Source Type: research
Formulation, Characterization and In Vitro Evaluation of Mesalamine and Bifidobacterium bifidum Loaded Hydrogel Beads in Capsule System for Colon Targeted Delivery
AAPS PharmSciTech. 2024 Mar 14;25(3):61. doi: 10.1208/s12249-024-02764-3.ABSTRACTMesalamine is a first-line drug for the treatment of inflammatory bowel diseases. However, its premature release associated with marketed formulations leads to adverse effects like gastric trouble, vomiting, and diarrhoea. To minimize these side effects, colon-targeted drug delivery is essential. Besides conventional pharmacotherapy, bifidogenic probiotics with anti-inflammatory activity has been reported to elicit a significant impact on the remission of ulcerative colitis. Bifidogenic probiotics being acid-labile necessitate developing a gas...
Source: AAPS PharmSciTech - March 15, 2024 Category: Drugs & Pharmacology Authors: Jagtar Singh Mohit Sharma Harmeet Singh Pinky Arora Puneet Utreja Shubham Kumar Source Type: research
Formulation, Characterization and In Vitro Evaluation of Mesalamine and Bifidobacterium bifidum Loaded Hydrogel Beads in Capsule System for Colon Targeted Delivery
AAPS PharmSciTech. 2024 Mar 14;25(3):61. doi: 10.1208/s12249-024-02764-3.ABSTRACTMesalamine is a first-line drug for the treatment of inflammatory bowel diseases. However, its premature release associated with marketed formulations leads to adverse effects like gastric trouble, vomiting, and diarrhoea. To minimize these side effects, colon-targeted drug delivery is essential. Besides conventional pharmacotherapy, bifidogenic probiotics with anti-inflammatory activity has been reported to elicit a significant impact on the remission of ulcerative colitis. Bifidogenic probiotics being acid-labile necessitate developing a gas...
Source: AAPS PharmSciTech - March 15, 2024 Category: Drugs & Pharmacology Authors: Jagtar Singh Mohit Sharma Harmeet Singh Pinky Arora Puneet Utreja Shubham Kumar Source Type: research
Machine Learning –Based Prediction of Pediatric Ulcerative Colitis Treatment Response Using Diagnostic Histopathology
The initial presentation of ulcerative colitis within the pediatric population exhibits a degree of uniformity, the majority characterized by extensive colitis at the time of diagnosis. However, the response to initial therapy demonstrates marked heterogeneity.1 It is challenging to discriminate which patients would successfully improve on corticosteroids followed by mesalamine therapy maintenance therapy and those who would benefit from early introduction of biologic therapy. The Clinical and Biological Predictors of Response to Standardized Pediatric Colitis Therapy (PROTECT) study, a multicenter inception cohort study, ...
Source: Gastroenterology - February 1, 2024 Category: Gastroenterology Authors: Xiaoxuan Liu, Surya Prasath, Iram Siddiqui, Thomas D. Walters, Lee A. Denson, PROTECT Consortium, Jasbir Dhaliwal Tags: Research Letters Source Type: research
Medical, endoscopic, and surgical therapies for the treatment of rectal cuffitis in ulcerative colitis patients with an ileal pouch-anal anastomosis: a systematic review
Patients who undergo ileal pouch-anal anastomosis (IPAA) without mucosectomy are left with a rectal cuff, which can develop inflammation known as cuffitis. Treatment of cuffitis typically includes mesalamine suppositories or corticosteroids, but individuals with refractory cuffitis may require advanced therapies, endoscopic intervention, or surgical intervention. The aim of this review is to summarize the existing literature regarding treatments options for cuffitis. (Source: Gastroenterology)
Source: Gastroenterology - January 25, 2024 Category: Gastroenterology Authors: Joseph Powers, Emma Dester, Mary Schleicher, Benjamin Cohen, Bret Lashner, Andrei Ivanov, Tracy Hull, Katherine Falloon, Taha Qazi Source Type: research
Pharmacoequity for Older Adults With Inflammatory Bowel Diseases
“Nothing’s worked, and I’m losing my life,” said the tired 73-year-old retired accountant who presented for a second opinion on the treatment of his ulcerative colitis (UC). Three years ago, he developed rectal bleeding and was diagnosed with UC. He did not have a sustained clinical response to mesalamine, vedolizumab, or infliximab, and remained on varying doses of prednisone for 2 years. His wife chimed in that they had intended to spend their retirement traveling, but he cannot even leave the house to go to the grocery store because he is so limited by his bowel movement frequency a nd urgency. (Source: Gastroenterology)
Source: Gastroenterology - January 24, 2024 Category: Gastroenterology Authors: Bharati Kochar, Ashwin N. Ananthakrishnan, Christine S. Ritchie Tags: Diversity, Equity, and Inclusion in GI Source Type: research
Pharmacoequity for Older Adults With Inflammatory Bowel Diseases
“Nothing’s worked, and I’m losing my life,” said the tired 73-year-old retired accountant who presented for a second opinion on the treatment of his ulcerative colitis (UC). Three years ago, he developed rectal bleeding and was diagnosed with UC. He did not have a sustained clinical response to mesalamine, vedolizumab, or infliximab, and remained on varying doses of prednisone for 2 years. His wife chimed in that they had intended to spend their retirement traveling, but he cannot even leave the house to go to the grocery store because he is so limited by his bowel movement frequency a nd urgency. (Source: Clinical...
Source: Clinical Gastroenterology and Hepatology - January 23, 2024 Category: Gastroenterology Authors: Bharati Kochar, Ashwin N. Ananthakrishnan, Christine S. Ritchie Tags: Diversity, Equity, and Inclusion in GI Source Type: research
The aminosalicylate - folate connection
Drug Metab Rev. 2024 Feb;56(1):80-96. doi: 10.1080/03602532.2024.2303507. Epub 2024 Jan 17.ABSTRACTTwo aminosalicylate isomers have been found to possess useful pharmacological behavior: p-aminosalicylate (PAS, 4AS) is an anti-tubercular agent that targets M. tuberculosis, and 5-aminosalicylate (5AS, mesalamine, mesalazine) is used in the treatment of ulcerative colitis (UC) and other inflammatory bowel diseases (IBD). PAS, a structural analog of pABA, is biosynthetically incorporated by bacterial dihydropteroate synthase (DHPS), ultimately yielding a dihydrofolate (DHF) analog containing an additional hydroxyl group in th...
Source: Drug Metabolism Reviews - January 17, 2024 Category: Drugs & Pharmacology Authors: Robert E London Source Type: research
Effects of Mesalamine Combined with Live Combined Bifidobacterium, Lactobacillus and Enterococcus Capsules on Intestinal Mucosa Barrier Function and Intestinal Microbiota in Mildly Active Crohn's Disease Patients
Conclusion: Mesalamine combined with Live combined Bifidobacterium, Lactobacillus and Enterococcus capsules are more effective in treating mildly active Crohn's disease.PMID:38159563 | DOI:10.1080/08941939.2023.2297565 (Source: Journal of Investigative Surgery)
Source: Journal of Investigative Surgery - December 30, 2023 Category: Surgery Authors: Meiqin Shen Yingqi Shi Zhenming Ge Junbo Qian Source Type: research
